Eyecare providers report slower Q3 and increased concern for the US economy and inflation rates

News
Article

The Vision Council’s Q3 Provider Insights study shows the sentiments of eye care providers nationwide as they manage practices and patient care.

©iamchamp / Adobe.stock.com

Image credit: ©iamchamp / Adobe.stock.com

The Vision Council has released the results of their Provider InSights research study for Q3 2023. This study explores the sentiments of eyecare providers in relation to the daily operations of their practices, the eyecare industry, and the American economy and was conducted in October and November of 2023. Those surveyed include opticians, optometrists, ophthalmologists, eyecare practice managers, eyecare practice owners and other professionals.1

The findings of the Q3 edition of the study show that eyecare providers in all the groups listed above feel that the outlook on the US economy has worsened since Q2 of 2023 and they are less confident about meeting their revenue goals for the year.1

Image courtesy of The Vision Council

Image courtesy of The Vision Council

In the press release1, Alysse Henkel, Senior Director of Market Research and Analytics at The Vision Council, noted that the impacts being felt by providers are also being felt by patients, saying, “Our latest findings from Q3 demonstrate that economic challenges continue to be a top concern for eyecare providers across the country, with responses showing that inflation is having the greatest effect on wholesale prices of eyewear and practice supplies. These impacts are reaching consumers—providers reported that patients continue to be price-sensitive when choosing eyewear and are becoming more price-sensitive about exams as well.”

Image courtesy of The Vision Council

Image courtesy of The Vision Council

The report also notes a few key points that are affecting providers as they manage their businesses:

  • Compared to Q1 and Q2, eyecare providers are less confident that they can meet their revenue goals.
  • Hiring remains the biggest challenge for eyecare providers in Q3.
  • Most providers expect staffing levels at their practices to remain the same in 2023.
  • Inflation challenges seen in Q1 and Q2 did not change significantly in Q3. Most eyecare providers said they increased prices for eyewear due to corresponding wholesale price increases.
  • Optometrists who treat childhood myopia report that parental and/or patient compliance with treatment and cost of treatment are the two biggest challenges in treating myopia successfully.1

In summary, this study sees that eyecare providers reported a less successful Q3 compared to Q1 and Q2, yet they maintain a positive outlook for the rest of 2023.

About the inSights Research Program
The Vision Council’s inSights Research Program launched in May 2022 and is built on a foundation of rigorous methodology and cutting-edge technology. The inSights Research Program provides a comprehensive perspective on the state of the optical industry through quarterly consumer survey reports; quarterly in-depth special reports on eyewear and eyecare products and topics; and an end-of-year market estimate and industry forecast.

Reference
  1. Inflation and staffing remain top concerns of eyecare providers according to the vision council’s Q3 provider insights research report. The Vision Council. November 28, 2023. Accessed Novermber 28, 2023.
Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
© 2024 MJH Life Sciences

All rights reserved.